From the Rigeneralab Centre for Regenerative Medicine; private practice; and Pegaso University.
Plast Reconstr Surg. 2020 Nov;146(5):987-994. doi: 10.1097/PRS.0000000000007248.
Microbotulinum refers to the systematic injection of tiny blebs of diluted botulinum toxin at repeated intervals into the skin. This targets the superficial fibers of the facial muscles, and weakens their insertion into the undersurface of the skin, which is responsible for the fine lines and wrinkles on the face. The authors present a pilot study based on quantitative evaluation, by means of a skin-scanning technology, of the aesthetic improvement of skin texture, microroughness, and enlarged pore size in a patient group treated with microbotulinum injections for cosmetic purposes.
The treatment was performed using a 32-gauge needle to deliver injections on a regular 1-cm grid from the forehead to the cheek and down to the jawline.
Sixty of the 62 patients completed the study. All analyzed parameters improved significantly (p < 0.0001) at 90 days with respect to the pretreatment time point (skin texture, -1.93 ± 0.51; microroughness, -2.48 ± 0.79; and pore diameter, 2.1 ± 0.43). Best results have been obtained in patients aged between 42.7 and 46.8 years, and standard deviation calculation allows us to recommend it in patients aged between 36.5 and 53 years.
The results of this pilot study suggest that intradermal botulinum toxin injection, or so-called microbotulinum, is a safe and effective method to treat skin flaws. Because of the high satisfaction rate among both physicians and patients, further studies are indeed mandatory to determine the optimal number of units needed for a longer and lasting effect with this particular novel dilution.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
微肉毒杆菌是指将稀释后的肉毒杆菌毒素微小气泡在间隔时间内反复系统注入皮肤。该方法针对的是面部肌肉的浅层纤维，减弱其在皮肤下表面的插入，从而改善面部的细纹和皱纹。作者通过皮肤扫描技术进行定量评估，对一组接受微肉毒杆菌注射美容治疗的患者的皮肤质地、微粗糙度和毛孔增大的美容改善效果进行了初步研究。
使用 32 号针，在额头、脸颊至下颌线以 1cm 的网格进行常规注射。
62 例患者中有 60 例完成了研究。与治疗前相比，所有分析参数在 90 天时均显著改善（p < 0.0001）（皮肤质地，-1.93 ± 0.51；微粗糙度，-2.48 ± 0.79；和毛孔直径，2.1 ± 0.43）。最佳效果出现在 42.7 至 46.8 岁的患者中，标准差计算允许我们建议 36.5 至 53 岁的患者接受该治疗。
这项初步研究的结果表明，真皮内肉毒杆菌毒素注射，又称微肉毒杆菌，是一种安全有效的治疗皮肤瑕疵的方法。由于医生和患者的满意度都很高，因此确实需要进一步的研究来确定这种特殊新型稀释剂的最佳单位数量，以达到更长和持久的效果。
临床问题/证据水平：治疗，IV。
